Kiniksa Pharmaceuticals International, PLC 10-Q quarterly reports
Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.
NASDAQ
Kiniksa Pharmaceuticals International, plc announced robust Q2 2026 financial results, driven by significant growth in ARCALYST net revenue and continued investment in pipeline development.
NASDAQ
Kiniksa Pharmaceuticals reported strong third-quarter 2025 financial results, driven by significant ARCALYST revenue growth and a shift to net income from a prior-year loss.
NASDAQ
Kiniksa Pharmaceuticals International, plc announced a significant increase in product revenue and a return to net income for the second quarter and first half of 2025, primarily driven by robust ARCALYST sales and progress in its KPL-387 clinical program.
NASDAQ
Kiniksa Pharmaceuticals announces a profitable first quarter in 2025, driven by significant growth in ARCALYST sales and strategic financial management.
NASDAQ
Kiniksa Pharmaceuticals reports a significant increase in Q3 revenue, primarily driven by strong sales of ARCALYST, while also detailing ongoing clinical development and strategic collaborations.
NASDAQ
10-Q: Kiniksa Pharmaceuticals Reports Strong Q2 Revenue Growth Amidst Strategic Manufacturing Transition
Kiniksa Pharmaceuticals reports a significant increase in product revenue for the second quarter of 2024, alongside ongoing strategic initiatives including a manufacturing technology transfer.
NASDAQ
Kiniksa Pharmaceuticals reports a significant increase in product revenue for the first quarter of 2024, driven by higher sales of ARCALYST.